Theraclion’s 2nd Generation Breakthrough Technology for Varicose Vein Treatments Ready to Launch
15 Octobre 2020 - 6:00PM
Business Wire
Regulatory News:
THERACLION (ISIN: FR0010120402; Mnemo: ALTHE, PEA-PME
eligible) (Paris:ALTHE), an innovative company specialized in
echotherapy treatment (using High Intensity Focused Ultrasound or
HIFU), has obtained CE Mark for the second generation of
SONOVEIN®, it’s HIFU treatment solution for varicose veins. It has
also signed a strategic supplier partnership with SuperSonic
Imaging (part of Hologic Inc.). Theraclion’s ambition is to give
all patients access to non-invasive varicose vein treatments.
CE marking of SONOVEIN S second generation breakthrough
technology by Theraclion
Theraclion’s SONOVEIN, launched in 2019, is a revolution in the
field of varicose vein treatment allowing treatment from outside
the body without the need of an operating theatre. SONOVEIN’s first
generation was intentionally rolled-out to a limited number of
centres and hospitals only and is currently installed in 5
countries. The commercial roll-out can now be accelerated thanks to
the CE marking of the second-generation system.
The new technology, called SONOVEIN S, remains the only
non-invasive option, without scars and without incisions. It now
integrates 16 times faster beam pulses streamlining the treatment
procedure and improving patient experience. This substantially
advanced technological solution could reduce the treatment duration
by up to 2 to 3 times and it eliminates the need for tumescence or
local anaesthesia. Importantly, the new device is designed to
integrate future upgrades on “plug-and-play” basis.
A strategic partnership signed with SuperSonic Imaging
(Hologic)
A strategic partnership agreement with SuperSonic Imaging has
been signed. SuperSonic Imagine is a pioneer in the field of
innovative ultrasound imaging. Its parent Hologic Inc. is a leading
global innovator in women’s health.
The incorporation of improved imaging could assist doctors in
further improving treatment times in the future.
Theraclion on track to revolutionize the large global market
for varicose vein treatment
Varicose veins affect an estimated 30% of the world’s adult
population and requires about 5 million medical procedures
annually. This second-generation disruptive technology is supported
by Key Opinion Leaders and represents a significant milestone in
Theraclion’s ambition to revolutionize varicose vein
treatments.
About Theraclion
Theraclion has developed an innovative high-tech echotherapy
solution using High Intensity Focused Ultrasound for the treatment
of varicose veins, SONOVEIN®. The treatment solution, which
obtained CE marking in April 2019, is based on the leading-edge
echotherapy treatment expertise developed over years by Theraclion
for non-invasive ablation of breast fibroadenomas and thyroid
nodules using its ECHOPULSE® solution. Further improvements to the
ECHOPULSE technology are the foundation for SONOVEIN to provide the
only non-invasive ablation therapy for varicose veins. This
procedure allows for a treatment without a catheter, chemical
injection, or incision. An operating room is not necessary, and the
treatment can be performed at a doctor’s offices or in clinics, as
well as in hospitals. Venous pathology is widespread worldwide and
generates around 5 million treatment procedures per year, according
to Millenium research Varicose Vein Device Market Study 2015.
Theraclion's technological solutions are based on high-tech
ultrasound medical imaging devices that are precise and easy to use
for practitioners.
Located in Malakoff, near Paris, Theraclion brings together a
team of 25 people, more than half of whom are dedicated to R&D
and clinical trials.
For more information, please visit the Theraclion website:
www.theraclion.com and the patient site:
https://echotherapie.com/echotherapy/
Theraclion is listed on Euronext Growth Paris Eligible for the
PEA-PME scheme Mnemonic: ALTHE - ISIN code: FR0010120402 LEI:
9695007X7HA7A1GCYD29
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201015005822/en/
Theraclion
David Caumartin Chief Executive Officer Tél : + 33 (0)1 55 48 90
70 david.caumartin@theraclion.com
Anja Kleber VP Marketing, Market Access & Sales Francophonia
anja.kleber@theraclion.com
Theraclion (EU:ALTHE)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Theraclion (EU:ALTHE)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024